Interpace Biosciences, Inc. (IDXG)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 32 | 41 | 32 | 40 | 47 | 39 | 36 | - |
| Operating profit | $m | 4 | 4 | ||||||
| Net profit | $m | -26 | -15 | -6 | 1 | 7 | 25 | 24 | - |
| EPS reported | $ | 0.89 | 4.42 | ||||||
| Operating cashflow per share | $ | 6.59 | 0.21 | ||||||
| Capex per share | $ | 0.40 | 0.02 | ||||||
| FCF per share | $ | 6.19 | 0.19 | ||||||
| Free cash flow | $m | 5 | 4 | ||||||
| Net debt | $m | -3 | -2 | ||||||
| Book value equity | $m | 22 | 23 | ||||||
| Book value per share | $ | 0.81 | 4.19 | ||||||
| Number of shares | m | 27.7 | 5.54 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 1.74 | ||||||
| P/B LTM | x | 0.24 | 0.23 | ||||||
| P/S LTM | x | 0.14 | 0.15 | ||||||
| P/FCF LTM | x | 0.99 | 1.33 | ||||||
| EV/EBITDA LTM | x | 0.86 | 0.84 | ||||||
| EV/Sales LTM | x | 0.11 | 1.11 | ||||||
| Earnings Yield LTM | % | +4.52% | +57.47% | ||||||
| FCF Yield | % | +100.62% | +75.42% | ||||||
| Quality | |||||||||
| ROE | % | +109.89% | +215.31% | ||||||
| ROIC | % | +14.00% | +11.30% | ||||||
| Operating margin | % | +10.55% | +9.32% | ||||||
| Gross margin | % | +62.31% | +62.53% | ||||||
| FCF/Sales | % | +14.14% | +12.09% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +122.50% | +1005.0% | ||||||
| Sales Growth YoY | % | -17.47% | -22.98% | ||||||
| Net Income Growth YoY | % | +266.68% | +264.77% | ||||||
| FCF Growth | % | +45.23% | +8.86% | ||||||
| Operating Profit Growth | % | -49.63% | -48.61% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 4.63 | 4.21 | ||||||
| Net Debt/EBITDA | x | -0.28 | -0.38 | ||||||
| EBIT/Net interest | x | 24.31 | 37.53 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.11 | -0.10 | ||||||
| Gross debt/equity | x | 0.05 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free